Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq.

Wienert B, Wyman SK, Richardson CD, Yeh CD, Akcakaya P, Porritt MJ, Morlock M, Vu JT, Kazane KR, Watry HL, Judge LM, Conklin BR, Maresca M, Corn JE.

Science. 2019 Apr 19;364(6437):286-289. doi: 10.1126/science.aav9023. Epub 2019 Apr 18.

2.

In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.

Carreras A, Pane LS, Nitsch R, Madeyski-Bengtson K, Porritt M, Akcakaya P, Taheri-Ghahfarokhi A, Ericson E, Bjursell M, Perez-Alcazar M, Seeliger F, Althage M, Knöll R, Hicks R, Mayr LM, Perkins R, Lindén D, Borén J, Bohlooly-Y M, Maresca M.

BMC Biol. 2019 Jan 15;17(1):4. doi: 10.1186/s12915-018-0624-2.

3.

In vivo CRISPR editing with no detectable genome-wide off-target mutations.

Akcakaya P, Bobbin ML, Guo JA, Malagon-Lopez J, Clement K, Garcia SP, Fellows MD, Porritt MJ, Firth MA, Carreras A, Baccega T, Seeliger F, Bjursell M, Tsai SQ, Nguyen NT, Nitsch R, Mayr LM, Pinello L, Bohlooly-Y M, Aryee MJ, Maresca M, Joung JK.

Nature. 2018 Sep;561(7723):416-419. doi: 10.1038/s41586-018-0500-9. Epub 2018 Sep 12.

4.

miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.

Huang WK, Akçakaya P, Gangaev A, Lee L, Zeljic K, Hajeri P, Berglund E, Ghaderi M, Åhlén J, Bränström R, Larsson C, Lui WO.

Exp Cell Res. 2018 Oct 1;371(1):287-296. doi: 10.1016/j.yexcr.2018.08.028. Epub 2018 Aug 24.

5.

MicroRNAs and Gastrointestinal Stromal Tumor.

Akçakaya P, Lui WO.

Adv Exp Med Biol. 2015;889:51-70. doi: 10.1007/978-3-319-23730-5_4. Review.

PMID:
26658996
6.

Secretome protein signature of human gastrointestinal stromal tumor cells.

Berglund E, Daré E, Branca RM, Akcakaya P, Fröbom R, Berggren PO, Lui WO, Larsson C, Zedenius J, Orre L, Lehtiö J, Kim J, Bränström R.

Exp Cell Res. 2015 Aug 1;336(1):158-70. doi: 10.1016/j.yexcr.2015.05.004. Epub 2015 May 14.

PMID:
25983130
7.

microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.

Akçakaya P, Caramuta S, Åhlen J, Ghaderi M, Berglund E, Östman A, Bränström R, Larsson C, Lui WO.

Br J Cancer. 2014 Nov 25;111(11):2091-102. doi: 10.1038/bjc.2014.548. Epub 2014 Oct 30.

8.

Functional role of the Ca²⁺-activated Cl⁻ channel DOG1/TMEM16A in gastrointestinal stromal tumor cells.

Berglund E, Akcakaya P, Berglund D, Karlsson F, Vukojević V, Lee L, Bogdanović D, Lui WO, Larsson C, Zedenius J, Fröbom R, Bränström R.

Exp Cell Res. 2014 Aug 15;326(2):315-25. doi: 10.1016/j.yexcr.2014.05.003. Epub 2014 May 10.

PMID:
24825187
9.

Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells.

Berglund E, Ubhayasekera SJ, Karlsson F, Akcakaya P, Aluthgedara W, Ahlen J, Fröbom R, Nilsson IL, Lui WO, Larsson C, Zedenius J, Bergquist J, Bränström R.

Anticancer Drugs. 2014 Apr;25(4):415-22. doi: 10.1097/CAD.0000000000000069.

PMID:
24361761
10.

Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma.

Caramuta S, Lee L, Ozata DM, Akçakaya P, Georgii-Hemming P, Xie H, Amini RM, Lawrie CH, Enblad G, Larsson C, Berglund M, Lui WO.

Blood Cancer J. 2013 Oct 11;3:e152. doi: 10.1038/bcj.2013.49.

11.

Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma.

Caramuta S, Lee L, Ozata DM, Akçakaya P, Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C, Lui WO.

Endocr Relat Cancer. 2013 Jul 4;20(4):551-64. doi: 10.1530/ERC-13-0098. Print 2013 Aug.

12.

Evidence for Ca(2+)-regulated ATP release in gastrointestinal stromal tumors.

Berglund E, Berglund D, Akcakaya P, Ghaderi M, Daré E, Berggren PO, Köhler M, Aspinwall CA, Lui WO, Zedenius J, Larsson C, Bränström R.

Exp Cell Res. 2013 May 1;319(8):1229-38. doi: 10.1016/j.yexcr.2013.03.001. Epub 2013 Mar 13.

13.

The functional SLC11A1 gene polymorphisms are associated with sarcoidosis in Turkish population.

Akçakaya P, Azeroglu B, Even I, Ates O, Turker H, Ongen G, Topal-Sarikaya A.

Mol Biol Rep. 2012 Apr;39(4):5009-16. doi: 10.1007/s11033-011-1297-x. Epub 2011 Dec 8.

PMID:
22160516
14.

Serum microRNA expression in pregnancies with preeclampsia.

Gunel T, Zeybek YG, Akçakaya P, Kalelioğlu I, Benian A, Ermis H, Aydınlı K.

Genet Mol Res. 2011 Nov 8;10(4):4034-40. doi: 10.4238/2011.November.8.5.

15.

The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.

Özata DM, Caramuta S, Velázquez-Fernández D, Akçakaya P, Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C, Lui WO.

Endocr Relat Cancer. 2011 Oct 27;18(6):643-55. doi: 10.1530/ERC-11-0082. Print 2011 Oct.

16.

miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer.

Akçakaya P, Ekelund S, Kolosenko I, Caramuta S, Ozata DM, Xie H, Lindforss U, Olivecrona H, Lui WO.

Int J Oncol. 2011 Aug;39(2):311-8. doi: 10.3892/ijo.2011.1043. Epub 2011 May 13.

PMID:
21573504
17.

Adenomatous polyposis coli-mediated control of beta-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors.

Miclea RL, Karperien M, Bosch CA, van der Horst G, van der Valk MA, Kobayashi T, Kronenberg HM, Rawadi G, Akçakaya P, Löwik CW, Fodde R, Wit JM, Robanus-Maandag EC.

BMC Dev Biol. 2009 Apr 8;9:26. doi: 10.1186/1471-213X-9-26.

Supplemental Content

Loading ...
Support Center